Pyramid Laboratories, Inc.

Form 483 issued April 11, 2019 · Costa Mesa, California

Inspection
Apr 1 – Apr 11, 2019
Observations
1
Pages
3
FEI number
1000160734

In short: On April 11, 2019, FDA issued a Form 483 with 1 observation to Pyramid Laboratories, Inc. in Costa Mesa, California (FEI 1000160734) after an inspection that ran Apr 1 – Apr 11, 2019. The investigators were Amanda L. Fyles, Christopher R. Czajka and Jolanna A. Norton. Most observations concern laboratory controls; the most-cited regulation is 21 CFR 211.165 (testing and release for distribution).

At a glance

1 of 1 observations on this 483 concern laboratory controls.

Laboratory controls1

Most cited: 21 CFR 211.165 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Pyramid Laboratories, Inc.?

FDA listed 1 observation on this Form 483, mostly about laboratory controls. The most-cited regulation is 21 CFR 211.165 (testing and release for distribution). The opening words of each observation are shown on this page.

Who inspected Pyramid Laboratories, Inc.?

Amanda L. Fyles, Christopher R. Czajka and Jolanna A. Norton are named on this Form 483, for the inspection of Apr 1 – Apr 11, 2019. Each investigator has a profile showing what they cite most.

When was Pyramid Laboratories, Inc. inspected by FDA?

The inspection ran Apr 1 – Apr 11, 2019, and the Form 483 is dated April 11, 2019.

How do I get the full Form 483 for Pyramid Laboratories, Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free